Pomerantz LLP, a renowned law firm specializing in corporate, securities, and antitrust class litigation, is currently conducting an investigation on behalf of investors of Repare Therapeutics Inc. (NASDAQ:RPTX). The investigation aims to determine whether Repare and certain officers and/or directors have been involved in securities fraud or other unlawful business practices. Investors who wish to participate in the investigation are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation stems from Repare’s recent press release, issued on February 12, 2024. In the release, Repare announced that it would regain global development and commercialization rights to camonsertib (RP-3500), a potential best-in-class oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase), following the termination of its collaboration agreement with Roche. The termination came after Roche conducted a review of its pipeline and considered evolving external factors.
The news of the termination had an impact on Repare’s stock price, which fell by $1.31 per share, or 15.58%, closing at $7.10 per share on February 13, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, has a long-standing reputation as a premier firm in the field of class action litigation. Founded by the late Abraham L. Pomerantz, a respected figure in the class action bar, the firm has been at the forefront of fighting for the rights of victims of securities fraud, breaches of fiduciary duty, and corporate misconduct for over 85 years. Pomerantz has successfully recovered billions of dollars in damages awards on behalf of class members.
Repare Therapeutics Inc. is a biotechnology company focused on developing novel precision oncology therapeutics. While the investigation by Pomerantz LLP is ongoing, it is important to note that the investigation is not a reflection of Repare’s overall business operations or the potential of its innovative therapies.
Investors and stakeholders are encouraged to stay informed about the progress of the investigation and any developments that may arise in the future.
Please note that this article is for informational purposes only and should not be considered as legal advice or a guarantee of similar outcomes.
